What Makes Eli Lilly And Co. (LLY) a Worthy Holding?
Alpha Wealth Funds, LLC, an investment management company, released its Q3 2025 letter for the “Insiders Fund”. A copy of the letter can be downloaded here. The fund returned 4.96% in September, bringing the YTD returns to 21.37%. This compares to the benchmark, S&P 500 September return of 3.65% and the year-to-date return through September […]
Weekend reading: protein
Alert to readers: Amazon.com displays listings for several more workbooks, study guides, and cookbooks purportedly based on my book, What to Eat Now (see previous post on this). I did not write any of them. Caveat emptor! ___________________________ Protein is the #1 food marketing trend for 2026 and is expected to be a big issue in […]
What if Less Can Be More? A New Approach to GLP-1 Weight Loss Medications
Microdosing won’t be the right choice for everyone. But for many patients, it’s already proving to be the difference between quitting obesity treatment early and making lasting progress. The post What if Less Can Be More? A New Approach to GLP-1 Weight Loss Medications appeared first on MedCity News.
10 top trends resetting consumer appetite in 2026
From GLP-1-driven taste shifts to protein pressure and portion realism, 2026 won’t kill indulgence – it’ll demand that bakery and snacks work harder for every bite.
GLP-1 Drugs Help Quell Asthma Among Teens Who Are Overweight or Obese
By Dennis Thompson HealthDay ReporterFRIDAY, Jan. 2, 2026 (HealthDay News) — Severe asthma attacks can be cut in half among teens with excess…
Remote Care Enables Effective Weight Loss With Semaglutide
Patients with overweight/obesity receiving branded semaglutide via a nationwide telehealth platform achieve weight-loss outcomes comparable to those in the STEP 1 trial of GLP-1 receptor agonist. Medscape Medical News
The expanding landscape of GLP-1 medicines
Nature Medicine, Published online: 02 January 2026; doi:10.1038/s41591-025-04124-5 This Review discusses the expansion of glucagon-like peptide-1 (GLP-1) medicines beyond type 2 diabetes and obesity, outlining opportunities for new indications, key questions around benefits and long-term safety, and areas of uncertainty requiring further research.
GLP-1 Drugs Such As Ozempic and Zepbound Help Quell Asthma Among Teens Who Are Overweight or Obese
FRIDAY, Jan. 2, 2026 — Severe asthma attacks can be cut in half among teens with excess weight by taking cutting-edge weight-loss drugs like Ozempic and Zepbound, a new study says.
Half as many teens needed asthma treatment at an emergency…
The good health news that could improve your life in 2026
This is Everyday Science with Clare Wilson, a subscriber-only newsletter from The i Paper. If you’d like to get this direct to your inbox every week, you can sign up here. Hello, and welcome back to Everyday Science. Are you in a post-Christmas slump? If so, lift your spirits by reading some good news, the progress that has been […]
Twenty Twenty-Five
2025 was… a year. And I made it to the end of that year. If you’re reading this, I imagine you did too and let’s celebrate that. But also not one without loss; of loved ones, of health, of relationships, of jobs, of liberties, of pursuits of happiness. Let’s mourn those. My year was mundane […]